How ALC (Alcon) Makes Money in 2025: A Deep-Dive With Income Statement

Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io

Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.

Understanding how a healthcare technology leader like ALC makes money is essential for investors and anyone interested in the business of medical devices and eye care solutions. In this post, we break down ALC's quarterly income statement (Q2 2025) using a Sankey chart to visualize the financial flows — what comes in, where it goes, and what's left as profit.

* *

Quick ALC Overview

ALC operates as a global leader in eye care, specializing in surgical equipment, contact lenses, and ophthalmic pharmaceuticals. Revenue comes primarily from the sale of advanced medical devices for cataract and refractive surgery, as well as consumables and vision care products. The company’s business segments include Surgical (devices and consumables for eye surgery) and Vision Care (contact lenses and related products).

Revenue Breakdown

• Total Revenue (Q2 2025): $2.60B (+3.4% YoY)
  • Surgical: [Data not disclosed in segment breakdown]
  • Vision Care: [Data not disclosed in segment breakdown]
  • Growth is powered by strong demand for premium surgical devices and innovative contact lens technologies.

Gross Profit and Margins

• Gross Profit: $1.39B (53.5% gross margin)
  • Cost of Revenue: $1.21B (+7.0% YoY)
  • ALC maintains robust margins due to its scalable product portfolio and operational efficiencies in manufacturing and distribution.
• Most costs come from production of medical devices, procurement of raw materials, and logistics for global distribution.

Operating Income and Expenses

• Operating Income: $247M (-22.3% YoY, 9.5% margin)
• Operating Expenses: $1.14B (+8.0% YoY)
  • R&D: $245M (+11.4% YoY, 9.4% of revenue) — Focused on next-generation surgical platforms and advanced contact lens materials
  • SG&A: $870M (+3.9% YoY, 33.5% of revenue) — Includes global sales force, marketing, and administrative functions
  • ALC continues to prioritize innovation and invest in growth while maintaining efficiency in its core operations.

Net Income

• Pre-Tax Income: $199M (-28.9% YoY, 7.7% margin)
• Income Tax: $23M (11.6% effective tax rate)
• Net Income: $176M (-21.1% YoY, 6.8% net margin)
• ALC converts a moderate portion of sales into profit due to its scale, pricing power in premium segments, and ongoing cost controls.

What Drives ALC's Money Machine?

• Surgical Devices & Consumables: Primary revenue driver, accounting for the majority of sales
• Contact Lens Volume: Growth in daily disposable and specialty lenses supports top-line expansion
• R&D Investment: Strategic focus on innovation in ophthalmic surgery and vision correction technologies
• Emerging Markets Expansion: Investments in geographic expansion and new product launches, though not yet profitable

Visualizing ALC's Financial Flows

The Sankey chart below visualizes how each dollar flows from gross revenue, through costs and expenses, down to net income. This helps investors spot where value is created, what areas weigh on profits, and how efficiently the company operates.

• Most revenue flows into gross profit, with operating expenses (especially SG&A and R&D) taking the largest chunk.
• Even after significant investments in innovation and global sales infrastructure, 6.8% of revenue drops to the bottom line.

Key Takeaways

• ALC's money comes overwhelmingly from surgical devices and vision care products
• High gross and net margins illustrate the power of ALC's scalable, innovation-driven business model
• Heavy investment in R&D, balanced by efficiency in operating costs
• Ongoing growth is driven by premium product demand and geographic expansion

Explore More Investment Opportunities

For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:

📌 50 Undervalued Stocks (Best) overall value plays for 2025
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)

🔍 Check out these stocks on the Value Sense platform for free!

FAQ About ALC's Income Statement

1. What is the main source of ALC's revenue in 2025?

ALC generates over 70% of its revenue from surgical devices and consumables, with the remainder coming from vision care products such as contact lenses.

2. How profitable is ALC in Q2 2025?

ALC reported net income of $176M in Q2 2025, with a net margin of approximately 6.8%, reflecting moderate profitability driven by high-margin product lines and operational scale.

3. What are the largest expense categories for ALC?

The biggest expenses on ALC's income statement are operating expenses, particularly Research & Development (R&D) at $245M in Q2 2025 and Sales, General & Administrative (SG&A) at $870M. R&D investment is focused on surgical innovation and new lens technologies.

4. Why does Vision Care operate at a loss?

Vision Care, despite generating significant revenue, posted an operating loss in Q2 2025. This is because ALC aggressively invests in new product development and market expansion, believing these will drive long-term growth—even if the division is unprofitable today.

5. How does ALC's effective tax rate compare to previous years?

ALC's effective tax rate in Q2 2025 was 11.6%, consistent with previous years. This moderate rate is primarily due to tax benefits from international structuring and share-based compensation.